Dysregulation of Aurora Kinases and AURKAIP1 Promoter Methylation as Potential Peripheral Diagnostic Biomarkers in Acute Myeloid Leukemia
Abstract
1. Introduction
2. Materials and Methods
2.1. Sample Collection
2.1.1. Real-Time Quantitative PCR Analysis (MIQE-Compliant)
2.1.2. DNA Isolation
2.1.3. MSRE-qPCR–Based DNA Methylation Analysis
2.2. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. Expression Levels of Target Genes
3.2.1. DNA Methylation Analyses
3.2.2. Diagnostic Performance of Aurora Kinase–Related Genes
3.2.3. Univariate Logistic Regression Analysis
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wang, B.; Reville, P.K.; Abbas, H.A. Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction. Curr. Opin. Pharmacol. 2025, 82, 102526. [Google Scholar] [CrossRef]
- Liu, H.; Sun, L.; Zhao, H.; Zhao, Z.; Zhang, S.; Jiang, S.; Cheng, T.; Wang, X.; Wang, T.; Shao, Y.; et al. Proteinase 3 depletion attenuates leukemia by promoting myeloid differentiation. Cell Death Differ. 2024, 31, 697–710. [Google Scholar] [CrossRef]
- Bruzzese, A.; Vigna, E.; Martino, E.A.; Labanca, C.; Caridà, G.; Mendicino, F.; Lucia, E.; Olivito, V.; Puccio, N.; Neri, A.; et al. TP53-Mutated Acute Myeloid Leukemia: Unanswered Questions. Hematol. Oncol. 2025, 43, e70106. [Google Scholar] [CrossRef]
- Cheung, V.; Michelis, F.V.; Sibai, H. Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine-First case report. EJHaem 2023, 4, 269–272. [Google Scholar] [CrossRef]
- Wang, Z. Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling. Cells 2021, 10, 3327. [Google Scholar] [CrossRef]
- Bertoli, C.; Skotheim, J.M.; de Bruin, R.A. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 2013, 14, 518–528. [Google Scholar] [CrossRef]
- Vats, P.; Saini, C.; Baweja, B.; Srivastava, S.K.; Kumar, A.; Kushwah, A.S.; Nema, R. Aurora kinases signaling in cancer: From molecular perception to targeted therapies. Mol. Cancer 2025, 24, 180. [Google Scholar] [CrossRef] [PubMed]
- Yan, M.; Wang, C.; He, B.; Yang, M.; Tong, M.; Long, Z.; Liu, B.; Peng, F.; Xu, L.; Zhang, Y.; et al. Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy. Med. Res. Rev. 2016, 36, 1036–1079. [Google Scholar] [CrossRef]
- Song, C.; Ma, R.; Yang, X.; Pang, S. The Deubiquitinating Enzyme USP14 Regulates Leukemic Chemotherapy Drugs-Induced Cell Apoptosis by Suppressing Ubiquitination of Aurora Kinase B. Cell. Physiol. Biochem. 2017, 42, 965–973. [Google Scholar] [CrossRef] [PubMed]
- Stafylidis, C.; Vlachopoulou, D.; Kontandreopoulou, C.N.; Diamantopoulos, P. Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia. J. Clin. Med. 2024, 13, 1082. [Google Scholar] [CrossRef] [PubMed]
- Badagliacca, R.; Fazio, M.; Stagno, F.; Mirabile, G.; Gerace, D.; Allegra, A. Curcumin and Acute Myeloid Leukemia: Synergistic Effects with Targeted Therapy. Int. J. Mol. Sci. 2025, 26, 9700. [Google Scholar] [CrossRef]
- Lakkaniga, N.R.; Wang, Z.; Xiao, Y.; Kharbanda, A.; Lan, L.; Li, H.Y. Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy. Med. Res. Rev. 2024, 44, 686–706. [Google Scholar] [CrossRef]
- Tsunematsu, T.; Arakaki, R.; Yamada, A.; Ishimaru, N.; Kudo, Y. The Non-Canonical Role of Aurora-A in DNA Replication. Front. Oncol. 2015, 5, 187. [Google Scholar] [CrossRef]
- Bertolin, G.; Bulteau, A.L.; Alves-Guerra, M.C.; Burel, A.; Lavault, M.T.; Gavard, O.; Le Bras, S.; Gagné, J.P.; Poirier, G.G.; Le Borgne, R.; et al. Aurora kinase A localises to mitochondria to control organelle dynamics and energy production. eLife 2018, 7, e38111. [Google Scholar] [CrossRef]
- Johnson, D.G.; Schneider-Broussard, R. Role of E2F in cell cycle control and cancer. Front. Biosci. 1998, 3, d447–d448. [Google Scholar] [CrossRef]
- Hsu, J.; Arand, J.; Chaikovsky, A.; Mooney, N.A.; Demeter, J.; Brison, C.M.; Oliverio, R.; Vogel, H.; Rubin, S.M.; Jackson, P.K.; et al. E2F4 regulates transcriptional activation in mouse embryonic stem cells independently of the RB family. Nat. Commun. 2019, 10, 2939. [Google Scholar] [CrossRef] [PubMed]
- Fouad, S.; Hauton, D.; D’Angiolella, V. E2F1: Cause and Consequence of DNA Replication Stress. Front. Mol. Biosci. 2020, 7, 599332. [Google Scholar] [CrossRef]
- Kent, L.N.; Leone, G. The broken cycle: E2F dysfunction in cancer. Nat. Rev. Cancer 2019, 19, 326–338. [Google Scholar] [CrossRef] [PubMed]
- Marei, H.E. Epigenetic regulators in cancer therapy and progression. NPJ Precis. Oncol. 2025, 9, 206. [Google Scholar] [CrossRef] [PubMed]
- Jian, J.; Yuan, C.; Ji, C.; Hao, H.; Lu, F. DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features. Clin. Exp. Med. 2023, 23, 2639–2649. [Google Scholar] [CrossRef]
- Goodyear, M.D.; Krleza-Jeric, K.; Lemmens, T. The Declaration of Helsinki. BMJ 2007, 335, 624–625. [Google Scholar] [CrossRef] [PubMed]
- Kwon, M.J.; Oh, E.; Lee, S.; Roh, M.R.; Kim, S.E.; Lee, Y.; Choi, Y.L.; In, Y.H.; Park, T.; Koh, S.S.; et al. Identification of novel reference genes using multiplatform expression data and their validation for quantitative gene expression analysis. PLoS ONE 2009, 4, e6162, Erratum in PLoS ONE 2009, 4, https://doi.org/10.1371/annotation/695436c7-3329-4bdc-9832-f427ecc33698. [Google Scholar] [CrossRef]
- Teixeira, A.; Carreira, L.; Abalde-Cela, S.; Sampaio-Marques, B.; Areias, A.C.; Ludovico, P.; Diéguez, L. Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review. Cancers 2023, 15, 1362. [Google Scholar] [CrossRef]
- Šestáková, Š.; Šálek, C.; Remešová, H. DNA Methylation Validation Methods: A Coherent Review with Practical Comparison. Biol. Proced. Online 2019, 21, 19. [Google Scholar] [CrossRef]
- Kurdyukov, S.; Bullock, M. DNA Methylation Analysis: Choosing the Right Method. Biology 2016, 5, 3. [Google Scholar] [CrossRef]
- Flashner, S.; Azizkhan-Clifford, J. Emerging Roles for Transcription Factors During Mitosis. Cells 2025, 14, 263. [Google Scholar] [CrossRef]
- Nath, S.; Agarwal, P. Editorial: Genetic regulation of mitosis and ploidy in cancer. Front. Genet. 2023, 14, 1264772. [Google Scholar] [CrossRef]
- Tang, A.; Gao, K.; Chu, L.; Zhang, R.; Yang, J.; Zheng, J. Aurora kinases: Novel therapy targets in cancers. Oncotarget 2017, 8, 23937–23954. [Google Scholar] [CrossRef] [PubMed]
- Krenn, V.; Musacchio, A. The Aurora B Kinase in Chromosome Bi-Orientation and Spindle Checkpoint Signaling. Front. Oncol. 2015, 5, 225. [Google Scholar] [CrossRef] [PubMed]
- Kasap, E.; Gerceker, E.; Boyacıoglu, S.; Yuceyar, H.; Yıldırm, H.; Ayhan, S.; Korkmaz, M. The potential role of the NEK6, AURKA, AURKB, and PAK1 genes in adenomatous colorectal polyps and colorectal adenocarcinoma. Tumour Biol. 2016, 37, 3071–3080. [Google Scholar] [CrossRef]
- Takeshita, M.; Koga, T.; Takayama, K.; Ijichi, K.; Yano, T.; Maehara, Y.; Nakanishi, Y.; Sueishi, K. Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer 2013, 80, 85–90. [Google Scholar] [CrossRef]
- Sorrentino, R.; Libertini, S.; Pallante, P.L.; Troncone, G.; Palombini, L.; Bavetsias, V.; Spalletti-Cernia, D.; Laccetti, P.; Linardopoulos, S.; Chieffi, P.; et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J. Clin. Endocrinol. Metab. 2005, 90, 928–935. [Google Scholar] [CrossRef]
- Lin, Z.Z.; Jeng, Y.M.; Hu, F.C.; Pan, H.W.; Tsao, H.W.; Lai, P.L.; Lee, P.H.; Cheng, A.L.; Hsu, H.C. Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer 2010, 10, 461. [Google Scholar] [CrossRef] [PubMed]
- Nikhil, K.; Shah, K. The significant others of aurora kinase a in cancer: Combination is the key. Biomark. Res. 2024, 12, 109. [Google Scholar] [CrossRef]
- Polverino, F.; Mastrangelo, A.; Guarguaglini, G. Contribution of AurkA/TPX2 Overexpression to Chromosomal Imbalances and Cancer. Cells 2024, 13, 1397. [Google Scholar] [CrossRef] [PubMed]
- Bejar, J.F.; DiSanza, Z.; Quartuccio, S.M. The oncogenic role of meiosis-specific Aurora kinase C in mitotic cells. Exp. Cell Res. 2021, 407, 112803. [Google Scholar] [CrossRef]
- Hosseini, S.; Hashemzadeh, S.; Estiar, M.A.; Ebrahimzadeh, R.; Fakhree, M.B.; Yousefi, B.; Sheikholeslami, S.; Modarresi, M.H.; Sakhinia, E. Expression Analysis of Aurora-C and Survivin, Two Testis-Specific Genes, in Patients with Colorectal Cancer. Clin. Lab. 2015, 61, 475–480. [Google Scholar] [CrossRef] [PubMed]
- Tsou, J.H.; Chang, K.C.; Chang-Liao, P.Y.; Yang, S.T.; Lee, C.T.; Chen, Y.P.; Lee, Y.C.; Lin, B.W.; Lee, J.C.; Shen, M.R.; et al. Aberrantly expressed AURKC enhances the transformation and tumourigenicity of epithelial cells. J. Pathol. 2011, 225, 243–254. [Google Scholar] [CrossRef]
- Gavriilidis, P.; Giakoustidis, A.; Giakoustidis, D. Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review. J. Clin. Med. Res. 2015, 7, 742–751. [Google Scholar] [CrossRef]
- Grisetti, L.; Garcia, C.J.C.; Saponaro, A.A.; Tiribelli, C.; Pascut, D. The role of Aurora kinase A in hepatocellular carcinoma: Unveiling the intriguing functions of a key but still underexplored factor in liver cancer. Cell Prolif. 2024, 57, e13641. [Google Scholar] [CrossRef]
- Denechaud, P.D.; Fajas, L.; Giralt, A. E2F1, a Novel Regulator of Metabolism. Front. Endocrinol. 2017, 8, 311. [Google Scholar] [CrossRef] [PubMed]
- Cacioppo, R.; Rad, D.; Pagani, G.; Gandellini, P.; Lindon, C. Post-transcriptional control drives Aurora kinase A expression in human cancers. PLoS ONE 2024, 19, e0310625. [Google Scholar] [CrossRef]
- Gao, Y.; Qiao, X.; Liu, Z.; Zhang, W. The role of E2F2 in cancer progression and its value as a therapeutic target. Front. Immunol. 2024, 15, 1397303. [Google Scholar] [CrossRef]
- Xu, Z.; Qu, H.; Ren, Y.; Gong, Z.; Ri, H.J.; Zhang, F.; Shao, S.; Chen, X.; Chen, X. Systematic Analysis of E2F Expression and Its Relation in Colorectal Cancer Prognosis. Int. J. Gen. Med. 2022, 15, 4849–4870. [Google Scholar] [CrossRef]
- Kao, Y.T.; Wu, C.H.; Wu, S.Y.; Lan, S.H.; Liu, H.S.; Tseng, Y.S. Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells. BMC Cancer 2017, 17, 277. [Google Scholar] [CrossRef][Green Version]
- Chang, C.H.; Liu, F.; Militi, S.; Hester, S.; Nibhani, R.; Deng, S.; Dunford, J.; Rendek, A.; Soonawalla, Z.; Fischer, R.; et al. The pRb/RBL2-E2F1/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry/exit by paracrine mechanisms. Nat. Commun. 2024, 15, 3580. [Google Scholar] [CrossRef] [PubMed]
- Zheng, Y.; Fei, H. High Expression of E2F4 Is an Adverse Prognostic Factor and Related to Immune Infiltration in Oral Squamous Cell Carcinoma. BioMed. Res. Int. 2022, 2022, 4731364. [Google Scholar] [CrossRef]
- Lim, S.K.; Gopalan, G. Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through an alternative ubiquitin-independent pathway. Biochem. J. 2007, 403, 119–127. [Google Scholar] [CrossRef]
- Rembiałkowska, N.; Rekiel, K.; Urbanowicz, P.; Mamala, M.; Marczuk, K.; Wojtaszek, M.; Żywica, M.; Radzevičiūtė-Valčiukė, E.; Novickij, V.; Kulbacka, J. Epigenetic Dysregulation in Cancer: Implications for Gene Expression and DNA Repair-Associated Pathways. Int. J. Mol. Sci. 2025, 26, 6531. [Google Scholar] [CrossRef]
- Mao, L.; Tang, Y.; Deng, M.J.; Huang, C.T.; Lan, D.; Nong, W.Z.; Li, L.; Wang, Q. A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer. J. Clin. Lab. Anal. 2022, 36, e24232. [Google Scholar] [CrossRef] [PubMed]
- Stout, S.A.; Lin, J.; Hernandez, N.; Davis, E.P.; Blackburn, E.; Carroll, J.E.; Glynn, L.M. Validation of Minimally-Invasive Sample Collection Methods for Measurement of Telomere Length. Front. Aging Neurosci. 2017, 9, 397. [Google Scholar] [CrossRef] [PubMed]



| Genes | Primers | Product Size (bp) |
|---|---|---|
| AURK A | F: 5′-ATT TTG GGT CAG TAC ATG CT-3′ R: 5′- GTC CAG GGT GCC ACA GAG A-3′ | 65 bp |
| AURK B | F: 5′-CTG CGC AGA GAG ATC GAA ATC-3′ R: 5′-AAT AGT TGT AGA GAC GCA GGA TGT TG-3′ | 67 bp |
| AURK C | F: 5′-GCT GCA GAA AAG CGA GAA ATT AG-3′ R: 5′-ATC TGC CAA CTC CTC TAT TAT CG-3′ | 64 bp |
| E2F1 | F: 5′-GGA CTC TTC GGA GAA CTT TCA GAT-3′ R: 5′-GGG CAC AGG AAA ACA TCG AT-3′ | 69 bp |
| E2F4 | F: 5′-ACC TCC TTT GAG CCC ATC AA-3′ R: 5′-CGT GTG GGA TCA AAG ATT TCT-3′ | 85 bp |
| AURKAIP1 | F: 5′-CTG AGA CGC AAG CAG ATC AAG T-3′ R: 5′-CCT TTA GCC CCG CCT TCA-3′ | 67 bp |
| ZNF207 | F: 5′-AAG TTG ATC CAT CCA GAT GAG GAT-3′ R: 5′-CGA GGA AGA TTA CGT TGATAC TTA GGT-3′ | 117 bp |
| Genes | Primers | Primers Size (bp) |
|---|---|---|
| E2F1 | F: 5′-GGTACCATCCGGACAAAG-3′ | 18 bp |
| R: 5′-GTTAAAGCCAATAGGAACCG-3′ | 20 bp | |
| E2F4 | F: 5′-GGAAGCGGAAGCAGTAAC-3′ | 18 bp |
| R: 5′-GACTGCTCACCACCAAGTT-3′ | 19 bp | |
| AURKAIP1 | F: 5′-CCTTCCACGTAACTCCACTT-3′ | 20 bp |
| R: 5′-GGATTGTGGGAAATGTAGTTT-3′ | 21 bp |
| Patients | Healthy Controls | |
|---|---|---|
| Sex | ||
| Male | 39 (47%) | 15 (54%) |
| Female | 44 (53%) | 13 (46%) |
| Age | ||
| <30 | 17 (20%) | 1 (4%) |
| 30–50 | 32 (39%) | 16 (57%) |
| >50 | 34 (41%) | 11 (39%) |
| Subtype | ||
| M1 | 4 (5%) | |
| M2 | 2 (2%) | |
| M3 | 16 (19%) | |
| M4 | 10 (12%) | |
| M4–M5 | 4 (5%) | |
| M5 | 4 (5%) | |
| M0 | 43 (52%) |
| Gene | AUC | Sensitivity (%) | Specificity (%) | Cut-Off | 95% CI |
|---|---|---|---|---|---|
| AURKA | 0.82 | 80.8 | 89.3 | 0.297 | 0.74–0.90 |
| AURKB | 0.95 | 96.1 | 83.3 | 0.003 | 0.90–0.99 |
| AURKC | 0.74 | 61.3 | 92.6 | 0.005 | 0.64–0.84 |
| E2F1 | 0.87 | 67.9 | 100 | 0.124 | 0.79–0.94 |
| E2F4 | 0.41 | 28.8 | 84.6 | 1.477 | 0.29–0.53 |
| AURKAIP1 | 0.71 | 46.2 | 96.4 | 0.287 | 0.61–0.81 |
| Combined Panel | 0.96 | 90.3 | 100 | 0.595 | 0.94–1.00 |
| Gene | OR | 95% CI | p-Value |
|---|---|---|---|
| AURKA | 0.31 | 0.17–0.55 | <0.001 |
| AURKB | 0.41 | 0.28–0.60 | <0.001 |
| AURKC | 0.68 | 0.53–0.88 | 0.003 |
| E2F4 | 1.25 | 0.91–1.72 | 0.17 |
| E2F1 | 0.42 | 0.28–0.63 | <0.001 |
| AURKAIP1 | 1.49 | 1.10–2.00 | 0.009 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Yalniz Kayim, Z.; Tuncer, S.B.; Celik Demirbas, B.; Gezer, U.; Sukruoglu Erdogan, O.; Kilic Erciyas, S.; Dalay, N.; Selim Yavuz, A.; Yasasever, V. Dysregulation of Aurora Kinases and AURKAIP1 Promoter Methylation as Potential Peripheral Diagnostic Biomarkers in Acute Myeloid Leukemia. Curr. Issues Mol. Biol. 2026, 48, 378. https://doi.org/10.3390/cimb48040378
Yalniz Kayim Z, Tuncer SB, Celik Demirbas B, Gezer U, Sukruoglu Erdogan O, Kilic Erciyas S, Dalay N, Selim Yavuz A, Yasasever V. Dysregulation of Aurora Kinases and AURKAIP1 Promoter Methylation as Potential Peripheral Diagnostic Biomarkers in Acute Myeloid Leukemia. Current Issues in Molecular Biology. 2026; 48(4):378. https://doi.org/10.3390/cimb48040378
Chicago/Turabian StyleYalniz Kayim, Zubeyde, Seref Bugra Tuncer, Betul Celik Demirbas, Ugur Gezer, Ozge Sukruoglu Erdogan, Seda Kilic Erciyas, Nejat Dalay, Akif Selim Yavuz, and Vildan Yasasever. 2026. "Dysregulation of Aurora Kinases and AURKAIP1 Promoter Methylation as Potential Peripheral Diagnostic Biomarkers in Acute Myeloid Leukemia" Current Issues in Molecular Biology 48, no. 4: 378. https://doi.org/10.3390/cimb48040378
APA StyleYalniz Kayim, Z., Tuncer, S. B., Celik Demirbas, B., Gezer, U., Sukruoglu Erdogan, O., Kilic Erciyas, S., Dalay, N., Selim Yavuz, A., & Yasasever, V. (2026). Dysregulation of Aurora Kinases and AURKAIP1 Promoter Methylation as Potential Peripheral Diagnostic Biomarkers in Acute Myeloid Leukemia. Current Issues in Molecular Biology, 48(4), 378. https://doi.org/10.3390/cimb48040378

